Search Results for: TERT

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
BRAF B-Raf proto-oncogene, serine/threonine kinase
  • Spry regulation of FGF signaling
  • Frs2-mediated activation
  • Frs2-mediated activation
  • ARMS-mediated activation
  • Signalling to p38 via RIT and RIN
  • RAF activation
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by MRAS-complex mutants
  • Sorafenib
  • XL281
  • RAF-265
  • PLX-4720
  • N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide
  • (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime
  • Vemurafenib
  • Regorafenib
  • Dabrafenib
  • Encorafenib
  • Fostamatinib
  • Ripretinib
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Thyroid cancer
  • Malignant melanoma
TERF1 telomeric repeat binding factor 1
  • Recognition and association of DNA glycosylase with site containing an affected pyrimidine
  • Cleavage of the damaged pyrimidine
  • Recognition and association of DNA glycosylase with site containing an affected purine
  • Recognition and association of DNA glycosylase with site containing an affected purine
  • Cleavage of the damaged purine
  • Cleavage of the damaged purine
  • Meiotic synapsis
  • Packaging Of Telomere Ends
  • Telomere Extension By Telomerase
  • Polymerase switching on the C-strand of the telomere
  • Processive synthesis on the C-strand of the telomere
  • Telomere C-strand (Lagging Strand) Synthesis
  • Telomere C-strand synthesis initiation
  • Removal of the Flap Intermediate from the C-strand
  • DNA Damage/Telomere Stress Induced Senescence
  • Inhibition of DNA recombination at telomere
MYC MYC proto-oncogene, bHLH transcription factor
  • Transcription of E2F targets under negative control by DREAM complex
  • NOTCH1 Intracellular Domain Regulates Transcription
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • MAPK6/MAPK4 signaling
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • TFAP2 (AP-2) family regulates transcription of cell cycle factors
  • RUNX3 regulates WNT signaling
  • Estrogen-dependent gene expression
  • Transcriptional regulation of granulopoiesis
  • Acetylsalicylic acid
  • Nadroparin
  • Choriocarcinoma
  • Penile cancer
  • Burkitt lymphoma
  • Oral cancer
  • Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
  • Multiple myeloma
  • Small cell lung cancer
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
  • Osteosarcoma
  • Kaposi's sarcoma
  • Laryngeal cancer
  • Breast cancer
  • Ovarian cancer
RAF1 Raf-1 proto-oncogene, serine/threonine kinase
  • Stimuli-sensing channels
  • Rap1 signalling
  • GP1b-IX-V activation signalling
  • CD209 (DC-SIGN) signaling
  • RAF activation
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by MRAS-complex mutants
  • Sorafenib
  • LErafAON
  • XL281
  • iCo-007
  • Cholecystokinin
  • Regorafenib
  • Dabrafenib
  • Fostamatinib
CCNE1 cyclin E1
  • G0 and Early G1
  • SCF(Skp2)-mediated degradation of p27/p21
  • DNA Damage/Telomere Stress Induced Senescence
  • Association of TriC/CCT with target proteins during biosynthesis
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • CDK-mediated phosphorylation and removal of Cdc6
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Cyclin E associated events during G1/S transition
  • G1/S-Specific Transcription
  • Cyclin D associated events in G1
  • p53-Dependent G1 DNA Damage Response
  • PTK6 Regulates Cell Cycle
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • RHOBTB3 ATPase cycle
  • Laryngeal cancer
  • Gastric cancer
FGFR4 fibroblast growth factor receptor 4
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • betaKlotho-mediated ligand binding
  • FGFR4 mutant receptor activation
  • FGFR4 ligand binding and activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade; FGFR4
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR4 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Heparin
  • Ponatinib
  • Lenvatinib
  • Erdafitinib
  • Pemigatinib
PPIA peptidylprolyl isomerase A
  • Platelet degranulation
  • Uncoating of the HIV Virion
  • Budding and maturation of HIV virion
  • Integration of provirus
  • Early Phase of HIV Life Cycle
  • Minus-strand DNA synthesis
  • Plus-strand DNA synthesis
  • Binding and entry of HIV virion
  • Assembly Of The HIV Virion
  • APOBEC3G mediated resistance to HIV-1 infection
  • Calcineurin activates NFAT
  • Basigin interactions
  • Neutrophil degranulation
  • Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
  • Cyclosporine
  • Proline
  • (3r)-1-Acetyl-3-Methylpiperidine
  • Ethyl Oxo(Piperidin-1-Yl)Acetate
  • Sanglifehrin A
  • Copper
  • Artenimol
XPO1 exportin 1
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Rev-mediated nuclear export of HIV RNA
  • NEP/NS2 Interacts with the Cellular Export Machinery
  • Downregulation of TGF-beta receptor signaling
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • Deactivation of the beta-catenin transactivating complex
  • HuR (ELAVL1) binds and stabilizes mRNA
  • RHO GTPases Activate Formins
  • MAPK6/MAPK4 signaling
  • Mitotic Prometaphase
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • EML4 and NUDC in mitotic spindle formation
  • Selinexor
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate WASPs and WAVEs
  • HDR through Single Strand Annealing (SSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Cyclin D associated events in G1
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX2 regulates osteoblast differentiation
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • ATP
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • XL228
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • Myristic acid
  • PD-166326
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
  • Fostamatinib
  • Brigatinib
  • Radotinib
  • Chronic myeloid leukemia (CML)
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
MDM2 MDM2 proto-oncogene
  • AKT phosphorylates targets in the cytosol
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • SUMOylation of transcription factors
  • SUMOylation of ubiquitinylation proteins
  • Trafficking of AMPA receptors
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Ub-specific processing proteases
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Methylation
  • Stabilization of p53
  • Regulation of RUNX3 expression and activity
  • Zinc
  • Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
  • Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Choriocarcinoma
  • Osteosarcoma
  • Glioma
  • Penile cancer
  • Alveolar rhabdomyosarcoma
MTOR mechanistic target of rapamycin kinase
  • PIP3 activates AKT signaling
  • Macroautophagy
  • MTOR signalling
  • mTORC1-mediated signalling
  • HSF1-dependent transactivation
  • Energy dependent regulation of mTOR by LKB1-AMPK
  • CD28 dependent PI3K/Akt signaling
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Regulation of TP53 Degradation
  • Regulation of PTEN gene transcription
  • Amino acids regulate mTORC1
  • Pimecrolimus
  • Sirolimus
  • Everolimus
  • Rimiducid
  • SF1126
  • XL765
  • Ridaforolimus
  • Temsirolimus
  • Fostamatinib
PDGFRA platelet derived growth factor receptor alpha
  • PIP3 activates AKT signaling
  • Downstream signal transduction
  • Signaling by PDGF
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Imatinib-resistant PDGFR mutants
  • Sunitinib-resistant PDGFR mutants
  • Regorafenib-resistant PDGFR mutants
  • Sorafenib-resistant PDGFR mutants
  • PDGFR mutants bind TKIs
  • Becaplermin
  • Imatinib
  • Sunitinib
  • XL820
  • Olaratumab
  • Pazopanib
  • Midostaurin
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Foreskin keratinocyte (neonatal)
  • Fostamatinib
  • Erdafitinib
  • Amuvatinib
  • Ripretinib
  • Glioma
YWHAZ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta
  • Activation of BAD and translocation to mitochondria
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Deactivation of the beta-catenin transactivating complex
  • Rap1 signalling
  • GP1b-IX-V activation signalling
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RHO GTPases activate PKNs
  • TP53 Regulates Metabolic Genes
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • Negative regulation of NOTCH4 signaling
  • Regulation of localization of FOXO transcription factors
  • Phenethyl Isothiocyanate
FZR1 fizzy and cell division cycle 20 related 1
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • SCF-beta-TrCP mediated degradation of Emi1
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • Phosphorylation of Emi1
  • Senescence-Associated Secretory Phenotype (SASP)
  • CDK-mediated phosphorylation and removal of Cdc6
  • Cyclin A:Cdk2-associated events at S phase entry
  • Transcriptional Regulation by VENTX
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
EIF2S1 eukaryotic translation initiation factor 2 subunit alpha
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • PERK regulates gene expression
  • PERK regulates gene expression
  • ABC-family proteins mediated transport
  • Translation initiation complex formation
  • Formation of the ternary complex, and subsequently, the 43S complex
  • Ribosomal scanning and start codon recognition
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • Recycling of eIF2:GDP
  • Response of EIF2AK4 (GCN2) to amino acid deficiency
  • Response of EIF2AK1 (HRI) to heme deficiency
TGFBR2 transforming growth factor beta receptor 2
  • Downregulation of TGF-beta receptor signaling
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • UCH proteinases
  • Foreskin fibroblast (neonatal)
  • Foreskin keratinocyte (neonatal)
  • Fostamatinib
  • Colorectal cancer
  • Loeys-Dietz syndrome (LDS)
  • Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
CDK6 cyclin dependent kinase 6
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
  • Regulation of RUNX1 Expression and Activity
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Alvocidib
  • (2S)-2-({6-[(3-Amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol
  • Fisetin
  • Palbociclib
  • Ribociclib
  • Abemaciclib
PTGES3 prostaglandin E synthase 3
  • Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • HSF1 activation
  • Attenuation phase
  • Aryl hydrocarbon receptor signalling
  • ESR-mediated signaling
  • Estrogen-dependent gene expression
  • Potential therapeutics for SARS
  • Acetaminophen
  • Grn163l
  • Copper
RUVBL1 RuvB like AAA ATPase 1
  • Telomere Extension By Telomerase
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • HATs acetylate histones
  • UCH proteinases
  • Ub-specific processing proteases
  • DNA Damage Recognition in GG-NER
  • Deposition of new CENPA-containing nucleosomes at the centromere
CCT5 chaperonin containing TCP1 subunit 5
  • Prefoldin mediated transfer of substrate to CCT/TriC
  • Formation of tubulin folding intermediates by CCT/TriC
  • Folding of actin by CCT/TriC
  • Association of TriC/CCT with target proteins during biosynthesis
  • Association of TriC/CCT with target proteins during biosynthesis
  • BBSome-mediated cargo-targeting to cilium
  • Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding

Page 2 out of 5 pages